Form Type:  SC TO-T/A
Filing Date:  4/7/2020 
CIK:  0001667633 
Address:  1490 O'BRIEN DRIVE, SUITE A 
City, State, Zip:  MENLO PARK, California 94025 
Telephone:  (650) 352-4150 
Fiscal Year:  12/31 
Description of Business
We are a clinical-stage immuno-oncology company focused on developing novel therapies to activate macrophages in the fight against cancer. We founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, we believe that our lead product candidate, magrolimab (formerly known as 5F9), can transform the treatment of cancer. Magrolimab has demonstrated promising activity in multiple Phase 1b/2 clinical trials in which we have treated over 400 cancer patients with solid or hematologic tumors. In March 2020, Forty Seven entered into a definitive agreement to be acquired by Gilead Sciences, Inc., which is expected to close during the second quarter of 2020. We are also preparing to advance two additional investigational compounds into clinical testing.
Register and access this filing in: